Wall Street brokerages forecast that AxoGen, Inc Common Stock (NASDAQ:AXGN) will announce earnings of ($0.05) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for AxoGen, Inc Common Stock’s earnings. AxoGen, Inc Common Stock posted earnings per share of ($0.06) in the same quarter last year, which indicates a positive year-over-year growth rate of 16.7%. The business is expected to issue its next earnings results on Wednesday, August 1st.
According to Zacks, analysts expect that AxoGen, Inc Common Stock will report full year earnings of ($0.13) per share for the current year. For the next financial year, analysts expect that the company will report earnings of ($0.01) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow AxoGen, Inc Common Stock.
AxoGen, Inc Common Stock (NASDAQ:AXGN) last issued its quarterly earnings results on Monday, April 30th. The medical equipment provider reported ($0.11) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.11). AxoGen, Inc Common Stock had a negative return on equity of 61.66% and a negative net margin of 18.83%. The company had revenue of $17.30 million for the quarter, compared to analysts’ expectations of $17.16 million. The company’s revenue was up 41.8% compared to the same quarter last year.
AXGN has been the topic of a number of recent analyst reports. Jefferies Financial Group raised their price target on AxoGen, Inc Common Stock to $45.00 and gave the stock a “buy” rating in a research report on Monday, March 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective (up from $37.00) on shares of AxoGen, Inc Common Stock in a research note on Tuesday, May 1st. JMP Securities raised their price objective on AxoGen, Inc Common Stock from $34.00 to $43.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 1st. ValuEngine raised AxoGen, Inc Common Stock from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of AxoGen, Inc Common Stock in a research note on Tuesday, June 26th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $41.29.
In related news, SVP Shawn F. Mccarrey sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 16th. The stock was sold at an average price of $43.47, for a total value of $434,700.00. Following the sale, the senior vice president now directly owns 33,057 shares of the company’s stock, valued at $1,436,987.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.86% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in AXGN. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of AxoGen, Inc Common Stock by 41.6% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock valued at $167,000 after purchasing an additional 1,345 shares in the last quarter. Princeton Capital Management LLC acquired a new stake in shares of AxoGen, Inc Common Stock during the first quarter valued at about $183,000. Xact Kapitalforvaltning AB acquired a new stake in shares of AxoGen, Inc Common Stock during the second quarter valued at about $266,000. Brown Advisory Inc. acquired a new stake in shares of AxoGen, Inc Common Stock during the first quarter valued at about $215,000. Finally, Paloma Partners Management Co acquired a new stake in shares of AxoGen, Inc Common Stock during the fourth quarter valued at about $215,000. 75.92% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ AXGN traded down $0.53 during mid-day trading on Wednesday, reaching $51.80. The company had a trading volume of 357,472 shares, compared to its average volume of 382,472. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.81 and a current ratio of 3.32. AxoGen, Inc Common Stock has a one year low of $14.30 and a one year high of $55.55. The stock has a market capitalization of $1.85 billion, a P/E ratio of -167.10 and a beta of 0.04.
About AxoGen, Inc Common Stock
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.